MS drugs go head-to-head

Alemtuzumab is better than two other common treatments for relapsing-remitting multiple sclerosis and just as good as a third, according to late breaking research presented at a major MS conference.

The analysis of data from the MSBase registry covered around 4,500 patients who were started on either alemtuzumab (Lemtrada), interferon-beta-1a (Rebif), natalizumab (Tysabri) or fingolimod (Gilenya).